Hold Transmedics (TMDX) despite recent earnings miss, as the company is investing heavily in future growth catalysts.
Source Post
Down 45%! Is it Finally Time to Move on From Transmedics Shares?
Playing FTSEMay 10, 2026
Transmedics (TMDX) experienced a significant stock price drop following its Q1 earnings report, primarily due to an EPS miss and margin compression. Despite the market's negative reaction, management has signaled 2026 as a heavy investment year focused on R&D for new products and international expansion. Key growth catalysts include the Enhance heart and Denovo lung trials, with FDA approval expected in 2026.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.